With Giovanni Caforio, MD, retiring in a few months, Chief Commercialization Officer Christopher Boerner, PhD, was promoted to CFO and Adam Lenkowsky switched from head of major markets to Dr. Boerner’s role, the drug company said.
Dr. Caforio will continue in his role as executive chair after Nov. 1 during a transition period for the board.
